EMA Recommends Granting a Marketing Authorisation for Camizestrant By Ogkologos - June 5, 2026 101 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... MOST POPULAR FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma August 14, 2020 COVID-19: “We’ve got so much on our plates” August 4, 2020 Breast Cancer Patient Credits Persistent Commercial Messaging for Saving Her Life June 9, 2020 Olaparib after Initial Treatment Delays Ovarian Cancer Progression November 20, 2018 Load more HOT NEWS Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical... What to Know About Using Activated Charcoal During Cancer COVID-19 Vaccines May Be Less Effective in Some People with Cancer
